Quality-Adjusted Time without Symptoms or Toxicity: Analysis of Axicabtagene Ciloleucel versus Standard of Care in Patients with Relapsed/Refractory Large B Cell Lymphoma

Authors:

Abstract
No abstract available
Funding Information
  • Kite Pharma Inc

This publication has 10 references indexed in Scilit: